Schedule 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. ___)*

VolitionRx Limited

(Name of Company)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

928661107

(CUSIP Number)

Guy Archibald Innes

1 Scotts Road

#24-05 Shaw Centre

Singapore 228208

+1 (646) 650-1351

With a copy to:

Marc G. Alcser, Esq.

Stradling Yocca Carlson & Rauth, P.C.

660 Newport Center Drive, Suite 1600

Newport Beach, CA 92660

(949) 725-4000

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

October 6, 2011

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a person’s initial filing on this form with respect to subject class of securities, and for any subsequent amendment containing information which would alter disclosures in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 928661107

13D

Page 2 of 8 Pages


1.	NAMES OF REPORTING PERSON Guy Archibald Innes
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) . (b) .
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions) PF, OO
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) (see instructions) .
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United Kingdom
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER 1,502,221(1)
		8.	SHARED VOTING POWER 49,726(2)
		9.	SOLE DISPOSITIVE POWER 1,502,221(1)
		10.	SHARED DISPOSITIVE POWER 49,726(2)
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,551,947(1)(2)
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) .
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.9% (1)(2)(3)
14.	TYPE OF REPORTING PERSON (see instructions) IN

(1)

Includes (i) 1,230,154 shares of VolitionRx Limited, or Company, common stock, par value $0.001 per share; (ii) options to purchase 65,000 shares of Company common stock that are exercisable within 60 days; and (iii) warrants to purchase 207,067 shares of Company common stock that are exercisable within 60 days, each held by Mr. Innes in his individual capacity.

(2)

Includes (i) 47,940 shares of Company common stock and (ii) warrants to purchase 1,786 shares of Company common stock that are exercisable within 60 days, each held in a bare trust, which is not a separate legal entity, of which Mr. Innes is the trustee, for the benefit of certain minors.

(3)

Based on 26,093,123 issued and outstanding shares of Company common stock as of November 10, 2016, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 10, 2016.

CUSIP No. 928661107

13D

Page 3 of 8 Pages

Explanatory Note:

On October 6, 2011, Mr. Innes acquired 430,000 shares of VolitionRx Limited, a Delaware corporation (the “Company”) common stock, par value $0.001 per share (the “Common Stock”). Mr. Innes’s beneficial ownership consisted of (i) 430,000 shares of Company Common Stock and (ii) warrants to purchase 100,000 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around this time, Mr. Innes had beneficial ownership of 6.4% of the Company.

On November 25, 2011, Mr. Innes was granted an option to purchase 30,000 shares of Company Common Stock subject to vesting. Mr. Innes’s beneficial ownership at the time the option was granted consisted of (i) 430,000 shares of Company Common Stock and (ii) warrants to purchase 100,000 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time of the option grant, Mr. Innes had beneficial ownership of 6.4% of the Company.

On May 11, 2012, Mr. Innes purchased 149,639 shares of Company Common Stock and a warrant to purchase 74,821 shares of Company Common Stock in connection with a Private Placement dated April 24, 2012. Mr. Innes’s beneficial ownership following the purchase consisted of (i) 579,639 shares of Company Common Stock, (ii) warrants to purchase 174,821 shares of Company Common Stock that are exercisable within 60 days and (iii) options to purchase 5,000 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time following the private placement, Mr. Innes had beneficial ownership of 8.0% of the Company.

On July 31, 2012, Mr. Innes purchased 289,287 shares of Company Common Stock in connection with a Private Placement dated July 31, 2012. Mr. Innes’s beneficial ownership following the purchase consisted of (i) 868,926 shares of Company Common Stock, (ii) warrants to purchase 174,821 shares of Company Common Stock that are exercisable within 60 days and (iii) options to purchase 5,000 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time following the private placement, Mr. Innes had beneficial ownership of 10.4% of the Company.

On November 25, 2013, Mr. Innes purchased 132,246 shares of Company Common Stock and a warrant to purchase 132,246 shares of Company Common Stock in connection with a Private Placement dated November 25, 2013. Mr. Innes’s beneficial ownership following the purchase consisted of (i) 1,064,341 shares of Company Common Stock, (ii) warrants to purchase 307,067 shares of Company Common Stock that are exercisable within 60 days and (iii) options to purchase 20,000 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time following the private placement, Mr. Innes had beneficial ownership of 11.6% of the Company. In addition, and in compliance with Item 5(c) of Schedule 13D, Mr. Innes made an open market purchase, using personal funds, of (x) 4,878 shares of Company Common Stock at $1.63 per share on November 14, 2013 and (y) 999 shares of Company Common Stock at $1.90 per share on November 14, 2013. The shares referenced in clauses (x) and (y) are included in clause (i) of this paragraph.

Between November of 2013 and March of 2014 the Company issued an aggregate of approximately 1.7 million shares of Company Common Stock which created a material change in the beneficial ownership of Mr. Innes. Mr. Innes’s beneficial ownership in March of 2014 consisted (i) 1,069,219 shares of Company Common Stock, (ii) warrants to purchase 307,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 25,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held by a bare trust, which is not a separate legal entity, of which Mr. Innes is the trustee, for the benefit of certain minors (the “Trust”), and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding in March of 2014, Mr. Innes had beneficial ownership of 10.6% of the Company. In addition, and in compliance with Item 5(c) of Schedule 13D, Mr. Innes, using personal funds, purchased (x) 38,884 shares of Company Common Stock and a warrant to purchase 5,484 shares of Company Common Stock from George Stephen Morris for an aggregate purchase price of approximately $45,793.28 on March 10, 2014 and subsequently transferred the shares and warrant to the Trust and (y) 3,572 shares of Company Common Stock and a warrant to purchase 1,786 shares of Company Common Stock from Satu Vainikka for an aggregate purchase price of approximately $4,206.72 on March 10, 2014 and subsequently transferred the shares and warrant to the Trust. The shares and warrants referenced in clauses (x) and (y) are included in clauses (iv) and (v) of this paragraph.

CUSIP No. 928661107

13D

Page 4 of 8 Pages

On August 18, 2014, Mr. Innes was granted an option to purchase 30,000 shares of Company Common Stock subject to vesting. Mr. Innes’s beneficial ownership at the time the option was granted consisted of (i) 1,069,219 shares of Company Common Stock, (ii) warrants to purchase 307,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 25,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held by the Trust, and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time of the option grant, Mr. Innes had beneficial ownership of 10.5% of the Company.

Between August of 2014 and February of 2015 the Company issued an aggregate of approximately 4.0 million shares of Company Common Stock which created a material change in the beneficial ownership of Mr. Innes. Mr. Innes’s beneficial ownership in February of 2015 consisted of (i) 1,127,741 shares of Company Common Stock, (ii) warrants to purchase 307,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 45,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held by the Trust, and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding in February of 2015, Mr. Innes had beneficial ownership of 8.6% of the Company. In addition, and in compliance with Item 5(c) of Schedule 13D, Mr. Innes, using personal funds, purchased 50,000 shares of Company Common Stock in a public offering at $3.75 per share. The shares purchased in the public offering are included in clause (i) of this paragraph.

On May 18, 2015, a previously granted option was amended which, for purposes of this filing, is deemed a cancellation of an outstanding option and a re-grant of a new option. Mr. Innes’s beneficial ownership at the time the option was amended consisted of (i) 1,127,741 shares of Company Common Stock, (ii) warrants to purchase 307,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 45,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held the Trust, and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time of the option amendment, Mr. Innes had beneficial ownership of 8.4% of the Company.

On July 23, 2015, Mr. Innes was granted an option to purchase 15,000 shares of Company Common Stock subject to vesting. Mr. Innes’s beneficial ownership at the time the option was granted consisted of (i) 1,127,741 shares of Company Common Stock, (ii) warrants to purchase 307,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 45,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held by the Trust, and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time of the option grant, Mr. Innes had beneficial ownership of 8.4% of the Company.

Between July of 2015 and March of 2016 the Company issued an aggregate of approximately 5.2 million shares of Company Common Stock which created a material change in the beneficial ownership of Mr. Innes. Mr. Innes’s beneficial ownership in March of 2016 consisted of (i) 1,127,741 shares of Company Common Stock, (ii) warrants to purchase 307,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 75,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held by the Trust, and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding in March of 2016, Mr. Innes had beneficial ownership of 6.6% of the Company.

On April 15, 2016, Mr. Innes was granted an option to purchase 30,000 shares of Company Common Stock subject to vesting. Mr. Innes’s beneficial ownership at the time the option was granted consisted of (i) 1,227,741 shares of Company Common Stock, (ii) warrants to purchase 207,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 75,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held by the Trust, and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time of the option grant, Mr. Innes had beneficial ownership of 6.7% of the Company. In addition, and in compliance with Item 5(c) of Schedule 13D, Mr. Innes exercised a warrant on March 22, 2016 for the purchase of 100,000 shares of Company Common Stock using personal funds in the amount of approximately $50,000. The Company Common Stock purchased from the warrant exercise are included in clause (i) of this paragraph.

CUSIP No. 928661107

13D

Page 5 of 8 Pages

On May 4, 2016, two outstanding warrants were amended, one for 74,821 shares of Company Common Stock held directly by Mr. Innes and one for 1,786 shares of Company Common Stock held by the Trust, which for purposes of this filing is deemed a cancellation of an outstanding warrant and a re-grant of a new warrant. Mr. Innes’s beneficial ownership at the time the warrants were amended consisted of (i) 1,227,741 shares of Company Common Stock, (ii) warrants to purchase 207,067 shares of Company Common Stock that are exercisable within 60 days, (iii) options to purchase 75,000 shares of Company Common Stock that are exercisable within 60 days, (iv) 42,456 shares of Company Common Stock held by the Trust, and (v) warrants held by the Trust to purchase 7,270 shares of Company Common Stock that are exercisable within 60 days. Based on the number of shares of Company Common Stock outstanding around the time of the warrant amendments, Mr. Innes had beneficial ownership of 6.6% of the Company.

From May 2016 until the date hereof Mr. Innes acquired shares of Company Common Stock through option and warrant exercises in non-material amounts.

The remaining disclosure set forth in this Schedule 13D will be based off Mr. Innes’s beneficial ownership as of the date hereof.

Item 1.

Security and Company

The securities to which this Schedule 13D (this “Statement”) relates are the shares of common stock, par value $0.001 per share of VolitionRx Limited, a Delaware corporation. The name and address of the principal executive offices of the Company are VolitionRx Limited, 1 Scotts Road, #24-05 Shaw Centre, Singapore 228208.

Item 2.

Identity and Background

(a)

Name

Guy Archibald Innes, an individual.

(b)

Business Address

The business address for Mr. Innes is 1 Scotts Road, #24-05 Shaw Centre, Singapore 228208.

(c)

Principal Business

The principal occupation of Mr. Innes is director of the Company.

(d)-(e)

No Convictions or Proceedings

During the last five years, Mr. Innes has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

During the last five years, Mr. Innes has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

Citizenship

Mr. Innes is a citizen of the United Kingdom.

CUSIP No. 928661107

13D

Page 6 of 8 Pages

Item 3.

Source and Amount of Funds or Other Consideration

Common Stock

Mr. Innes acquired 430,000 shares of Company Common Stock, in October of 2011, in exchange for his shares of Singapore Volition Pte Ltd. (“Singapore Volition”), the predecessor entity of the Company, pursuant to the Share Exchange Agreement between the Company, Singapore Volition and the shareholders of Singapore Volition, dated September 26, 2011. In May of 2012, Mr. Innes used approximately $261,866 in personal funds to purchase 149,639 shares of Company Common Stock in a Private Placement dated April 24, 2012. In July of 2012, Mr. Innes used approximately $506,250 in personal funds to purchase 289,287 shares of Company Common Stock in a Private Placement dated July 31, 2012. In March of 2013, Mr. Innes used approximately $114,583 in personal funds to purchase 57,292 shares of Company Common Stock in a Private Placement dated March 25, 2013. In November of 2013, Mr. Innes used approximately (i) $7,951 in personal funds to purchase 4,878 shares of Company Common Stock on the open market, (ii) $1,898 in personal funds to purchase 999 shares of Company Common Stock on the open market, and (iii) $271,102 in personal funds to purchase 132,246 shares of Company Common Stock in a Private Placement dated November 25, 2013. In December of 2013, Mr. Innes used approximately (i) $10,000 in personal funds to purchase 4,878 shares of Company Common Stock on the open market, (ii) $45,793 in personal funds to purchase 38,884 shares of Company Common Stock from George Stephen Morris, which shares were transferred to the Trust, and (iii) $4,207 in personal funds to purchase 3,572 shares of Company Common Stock from Satu Vainikka, which shares were transferred to the Trust. In September of 2014, Mr. Innes used approximately $18,748 in personal funds to purchase 8,522 shares of Company Common Stock from the Company in a Private Placement dated September 24, 2014. In February of 2015, Mr. Innes used approximately $187,500 in personal funds to purchase 50,000 shares of Company Common Stock in a public offering. In March of 2016, Mr. Innes used approximately $50,000 in personal funds to exercise a warrant for the purchase of 100,000 shares of Company Common Stock. In May of 2016, Mr. Innes elected a cashless exercise of 5,000 vested options. Of the 5,000 vested options exercised, 4,238 were held and cancelled by the Company as payment for the exercise which resulted in the acquisition of 762 shares of Company Common Stock. In June of 2016, the Trust used approximately $2,742 in personal funds to exercise a warrant for the purchase of 5,484 shares of Company Common Stock. In November of 2016, Mr. Innes elected a cashless exercise of 5,000 vested options. Of the 5,000 vested options exercised, 3,349 where held and canceled by the Company as payment for the exercise which resulted in the acquisition of 1,651 shares of Company Common Stock.

Options

The options to purchase 65,000 shares of Company Common Stock that are exercisable within the next 60 days were received, at no cost, by Mr. Innes on November 25, 2011, August 18, 2014 and July 23, 2015, respectively.

Warrants

The warrants to purchase 207,067 shares of Company Common Stock that are exercisable within the next 60 days were received by Mr. Innes in connection with the Private Placements, dated April 24, 2012 and November 25, 2013, respectively. The warrants to purchase 1,786 shares of Company Common Stock that are exercisable within the next 60 days were received by the Trust in connection with the share purchase from Satu Vainikka on December 27, 2013.

CUSIP No. 928661107

13D

Page 7 of 8 Pages

Item 4.

Purpose of Transaction

Mr. Innes holds his shares of Company Common Stock for investment purposes. Mr. Innes may, from time to time, depending on market conditions and other considerations, purchase additional shares or dispose of some or all of the shares held by him.

(a)

Mr. Innes has been granted options to purchase 95,000 shares of Company Common Stock. At the time of this Statement 65,000 options are exercisable within the next 60 days. The remaining 30,000 options will vest on April 15, 2017. In addition, Mr. Innes holds directly a warrant to purchase 207,067 shares of Company Common Stock that is exercisable within the next 60 days and indirectly through the Trust a warrant to purchase 1,786 shares of Company Common Stock that is exercisable within the next 60 days.

Mr. Innes has no current plans or proposals which relate to, or may result in, any of the matters listed in Items 4(b)-(j) of Schedule 13D.

Item 5.

Interest in Securities of the Company

Based upon the Company’s most recent report on Form 10-Q for the period ended September 30, 2016, filed with the Securities and Exchange Commission on November 10, 2016, there were 26,093,123 shares of Company Common Stock issued and outstanding as of November 10, 2016. The percentages of ownership set forth below are based on there being 26,093,123 shares of Company Common Stock outstanding.

(a) and (b)

As of the date hereof the beneficial ownership of Company Common Stock by Mr. Innes is as follows:

Mr. Innes has sole investment and voting power with respect to 1,502,221 shares of Company Common Stock and may be deemed to share investment or voting power with respect to 49,726 shares of Company Common Stock. In aggregate, Mr. Innes may be deemed to beneficially own 1,551,947 shares of Company Common Stock, which reflects 5.9% beneficial ownership of the Company.

(c)

Mr. Innes acquired 1,651 shares of Company Common Stock on November 18, 2016. The acquisition was the result of a cashless exercise of 5,000 options. The exercise price for the options was $3.00 per share and the 3,349 shares of Common Stock retained by the Company for cancellation as payment of the exercise price had a fair market value of $4.48 per share. No shares were sold by Mr. Innes or the Company in such cashless exercise transaction.

(d)

Not applicable.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Company

On September 30, 2016, the Company entered into an underwriting agreement with National Securities Corporation in connection with a public offering (the “Offering”). In connection with the Offering, Mr. Innes entered into a customary “lock-up” agreement with the underwriters pursuant to which they agreed, subject to specific exceptions, not to sell any of their shares of Company Common Stock for 90 days following the date of the final prospectus, or September 30, 2016. The description of the Lock-Up Agreement contained herein is qualified in its entirety by reference to Schedule IV of Exhibit 1.1 to the Company’s Current Report on Form 8-K which was filed with the SEC on September 30, 2016 and is incorporated herein by reference.

Item 7.

Material to be Filed as Exhibits


Exhibit I		Form of Lock-Up Agreement, by and among Mr. Innes and the Underwriters (incorporated herein by reference from Schedule IV to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed on September 30, 2016 (File No. 001-36833)).

CUSIP No. 928661107

13D

Page 8 of 8 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 28, 2016

Guy Archibald Innes

/s/ Guy Archibald Innes

Guy Archibald Innes

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: Provided, however, That a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.